Info Text – Right Hand Column Placeholder
Refresh After Saving to Remove
New Lab Space
Click here to see our new lab space!
Research Program:
NIH Grant R01 https://app.dimensions.ai/details/grant/grant.2508236
NIH Grant R01 https://app.dimensions.ai/details/grant/grant.8383778
1. American Diabetic AssociationTitle: Gene therapy in Diabetic RetinopathyRole: PIDollar amount: $ 345,000Start date 12/2022, End date: 11/20252. International Retinal Research Foundation (IRRF) Pilot GrantTitle: Gene silencing in age-related macular degeneration (AMD)Role: PIDollar amount: $ 100,000Start date 07/2024, End date: 06/2026
3. National Institute of Health R01EY029693Title: In vivo molecular imaging of vascular disease the retinaRole: PIDollar amount: $ 3,600,609Start date 3/2013, End date: 5/2024.4. National Institute of Health R01EY023397Title: In vivo molecular imaging of the retinaRole: PIDollar amount: $ 2,073,327Start date 3/2019, End date: 2/2025.
5. BrightFocus Foundation Macular Degeneration Research Grant
Title: Hairpin-DNA functionalized nanoformulation for AMD
Role: PI
Dollar amount: $ 200,000
Start date 7/2019, End date: 6/2022.
6. National Institute of Health sponsored MICROMouse Program
(MMPC)
Title: Hairpin-DNA functionalized nanoformulation for AMD
Role: PI
Dollar amount: $ 75,000
Start date 01/2018, End date: 12/2018.
7. Knights Templar Eye Foundation Pediatric Ophthalmology
Career Starter Grant
Title: In vivo Imaging of Retinal Hypoxia in a Preclinical Model of Retinopathy of Prematurity
Role: PI
Dollar amount: $ 130,000
Start date 07/2016, End date: 03/2019.
8. Carl Marshall Reeves & Mildred Almen Reeves Foundation
Title: Equipemtn Grant age-related macular degeneration (AMD)
Role: PI
Dollar amount: $ 227,100
Start date 10/2019, End date: 09/2024.
Research Interests:
Uddin Lab is focused on the development of molecular imaging technologies including optical imaging, optical coherence tomography (OCT) and nano-scale engineering to identify molecular targets for early disease-detection and treatments in ophthalmology, vascular medicine and oncology.
Dr. Uddin is currently using optical imaging techniques and nanotechnology-based approaches for diagnosis and drug delivery in preclinical models of diabetic retinopathy (DR), retinopathy of prematurity (ROP), retinal vein occlusion (RVO) and age-related macular degeneration (AMD).
Dr. Uddin is highly collaborative and his long-term collaborators are Dr. John S. Penn and Dr. Craig Duvall.